{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:57:00Z","timestamp":1772470620936,"version":"3.50.1"},"posted":{"date-parts":[[2026,1,12]]},"group-title":"In Review","reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,2]]},"abstract":"<title>Abstract<\/title>\n                <p>Background\n Anxiety disorders (ANX) affect 30\u201360% of individuals with bipolar disorder (BD), yet limited research has systematically examined clinical characteristics and treatment patterns in this comorbid population. This study investigated demographic, clinical, and pharmacotherapeutic differences between individuals with BD with and without comorbid ANX.\nMethods\n Cross-sectional data from 2,225 adults with BD enrolled in the Mayo Clinic Bipolar Disorder Biobank were analyzed. Participants were assessed for comorbid ANX, demographics, clinical characteristics, medication use, and treatment response using the Alda-A scale.\nResults\n Overall, 61% (n\u2009=\u20091,366) had comorbid ANX. Individuals with BD\u2009+\u2009ANX were younger (40.4 vs. 43.6 years, p\u2009&lt;\u20090.001), more likely female (66.6% vs. 54.8%, p\u2009&lt;\u20090.001), and exhibited higher rates of rapid cycling (64.2% vs. 45.2%, p\u2009&lt;\u20090.001), suicide attempts (40.4% vs. 24.8%, p\u2009&lt;\u20090.001), substance use disorders (63.5% vs. 54.8%, p\u2009&lt;\u20090.001), and somatic comorbidities (MCIRS: 6.68 vs. 5.42, p\u2009&lt;\u20090.001). Pharmacotherapeutically, BD\u2009+\u2009ANX individuals were less likely to receive lithium (37.1% vs. 47.8%, p\u2009=\u20090.005) and valproic acid (21.7% vs. 29.6%, p\u2009=\u20090.047), but more likely to receive antidepressants (53.8% vs. 39.5%, p\u2009&lt;\u20090.001), benzodiazepines (39.9% vs. 26.6%, p\u2009&lt;\u20090.001), and gabapentinoids (8.5% vs. 4.5%, p\u2009&lt;\u20090.001). Notably, 17.3% of BD\u2009+\u2009ANX individuals received antidepressants without mood stabilizer coverage. Treatment response (Alda-A) scores were significantly lower in BD\u2009+\u2009ANX for lithium (4.91 vs. 6.05, p\u2009&lt;\u20090.001), mood-stabilizing anticonvulsants (5.09 vs. 6.22, p\u2009&lt;\u20090.001), and second-generation antipsychotics (4.67 vs. 5.73, p\u2009&lt;\u20090.001). Similar patterns were observed in both BD-I and BD-II subtypes.\nConclusions\n Individuals with BD\u2009+\u2009ANX represent a more severely affected subgroup with distinct prescribing patterns favoring antidepressants over mood stabilizers and attenuated mood stabilizers response. These findings highlight the need for anxiety-informed treatment algorithms recognizing anxiety comorbidity as a negative prognostic factor.<\/p>","DOI":"10.21203\/rs.3.rs-8503080\/v1","type":"posted-content","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:41:18Z","timestamp":1768196478000},"source":"Crossref","is-referenced-by-count":0,"title":["The Anxious Bipolar Phenotype: Clinical Complexity and Treatment Resistance"],"prefix":"10.21203","author":[{"given":"Balwinder","family":"Singh","sequence":"first","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada Man-Choi","family":"Ho","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Coombes","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Romo-Nava","sequence":"additional","affiliation":[{"name":"Lindner Center of HOPE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Cuellar-Barboza","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Gardea-Res\u00e9ndez","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bond","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Prieto","sequence":"additional","affiliation":[{"name":"Universidad de Los Andes, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Veldic","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Pendegraft","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"McElroy","sequence":"additional","affiliation":[{"name":"Lindner Center of HOPE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Biernacka","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Frye","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1176\/ajp.152.8.1130","article-title":"Antidepressant-induced mania and cycle acceleration: a controversy revisited","volume":"152","author":"Altshuler LL","year":"1995","unstructured":"Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152:1130\u20138. https:\/\/doi.org\/10.1176\/ajp.152.8.1130.","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41398-022-01917-x","article-title":"Neural network of bipolar disorder: Toward integration of neuroimaging and neurocircuit-based treatment strategies","volume":"12","author":"Bi B","year":"2022","unstructured":"Bi B, Che D, Bai Y. Neural network of bipolar disorder: Toward integration of neuroimaging and neurocircuit-based treatment strategies. Transl Psychiatry. 2022;12:143. https:\/\/doi.org\/10.1038\/s41398-022-01917-x.","journal-title":"Transl Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13208","article-title":"Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative","author":"Burdick KE","year":"2022","unstructured":"Burdick KE, Millett CE, Yocum AK, Altimus CM, Andreassen OA, Aubin V, Belzeaux R, Berk M, Biernacka JM, Blumberg HP, Cleare AJ, Diaz-Byrd C, Dubertret C, Etain B, Eyler LT, Forester BP, Fullerton JM, Frye MA, Gard S, Godin O, Haffen E, Klaus F, Lagerberg TV, Leboyer M, Martinez-Aran A, McElroy S, Mitchell PB, Olie E, Olorunfemi P, Passerieux C, Peters AT, Pham DL, Polosan M, Potter JR, Sajatovic M, Samalin L, Schwan R, Shanahan M, Sole B, Strawbridge R, Stuart AL, Torres I, Ueland T, Vieta E, Williams LJ, Wrobel AL, Yatham LN, Young AH, Nierenberg AA, McInnis MG. Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. Bipolar Disord. 2022. https:\/\/doi.org\/10.1111\/bdi.13208.","journal-title":"Bipolar Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1192\/bjp.bp.110.081992","article-title":"Effects of anxiety on the long-term course of depressive disorders","volume":"200","author":"Coryell W","year":"2012","unstructured":"Coryell W, Fiedorowicz JG, Solomon D, Leon AC, Rice JP, Keller MB. Effects of anxiety on the long-term course of depressive disorders. Br J Psychiatry. 2012;200:210\u20135. https:\/\/doi.org\/10.1192\/bjp.bp.110.081992.","journal-title":"Br J Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40345-020-00184-3","article-title":"Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection","volume":"8","author":"Cuellar-Barboza AB","year":"2020","unstructured":"Cuellar-Barboza AB, McElroy SL, Veldic M, Singh B, Kung S, Romo-Nava F, Nunez NA, Cabello-Arreola A, Coombes BJ, Prieto M, Betcher HK, Moore KM, Winham SJ, Biernacka JM, Frye MA. Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. Int J Bipolar Disord. 2020;8:23. https:\/\/doi.org\/10.1186\/s40345-020-00184-3.","journal-title":"Int J Bipolar Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/bdi.13125","article-title":"Efficacy and acceptability of pharmacotherapy for comorbid anxiety symptoms in bipolar disorder: A systematic review and meta-analysis","volume":"23","author":"Cullen C","year":"2021","unstructured":"Cullen C, Kappelmann N, Umer M, Abdolizadeh A, Husain MO, Bonato S, Sharma G, Xue S, Ortiz A, Kloiber SM, Mulsant BH, Husain MI. Efficacy and acceptability of pharmacotherapy for comorbid anxiety symptoms in bipolar disorder: A systematic review and meta-analysis. Bipolar Disord. 2021;23:754\u201366. https:\/\/doi.org\/10.1111\/bdi.13125.","journal-title":"Bipolar Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.64719\/pb.4545","article-title":"Systematic Review of Second-Generation Antidepressant Monotherapy for Acute Bipolar-II Depression","volume":"55","author":"Elmosalamy A","year":"2025","unstructured":"Elmosalamy A, Keeth N, Park JH, Gerberi DJ, McElroy SL, Frye MA, Singh B. Systematic Review of Second-Generation Antidepressant Monotherapy for Acute Bipolar-II Depression. Psychopharmacol Bull. 2025;55:79\u2013103. https:\/\/doi.org\/https:\/\/doi.org\/10.64719\/pb.4545.","journal-title":"Psychopharmacol Bull"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1176\/appi.ajp.157.6.956","article-title":"Anxiety as a correlate of response to the acute treatment of bipolar I disorder","volume":"157","author":"Feske U","year":"2000","unstructured":"Feske U, Frank E, Mallinger AG, Houck PR, Fagiolini A, Shear MK, Grochocinski VJ, Kupfer DJ. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry. 2000;157:956\u201362. https:\/\/doi.org\/10.1176\/appi.ajp.157.6.956.","journal-title":"Am J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4088\/JCP.22ed14609","article-title":"Prescribing Guideline for Valproic Acid and Women of Reproductive Potential: Forget It Exists","author":"Freeman MP","year":"2022","unstructured":"Freeman MP. Prescribing Guideline for Valproic Acid and Women of Reproductive Potential: Forget It Exists. J Clin Psychiatry. 2022;83. https:\/\/doi.org\/10.4088\/JCP.22ed14609.","journal-title":"J Clin Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0165-0327(00)00299-8","article-title":"The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues","volume":"68","author":"Freeman MP","year":"2002","unstructured":"Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord. 2002;68:1\u201323. https:\/\/doi.org\/10.1016\/s0165-0327(00)00299-8.","journal-title":"J Affect Disord"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40345-015-0030-4","article-title":"Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses","volume":"3","author":"Frye MA","year":"2015","unstructured":"Frye MA, McElroy SL, Fuentes M, Sutor B, Schak KM, Galardy CW, Palmer BA, Prieto ML, Kung S, Sola CL, Ryu E, Veldic M, Geske J, Cuellar-Barboza A, Seymour LR, Mori N, Crowe S, Rummans TA, Biernacka JM. Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses. Int J Bipolar Disord. 2015;3:30. https:\/\/doi.org\/10.1186\/s40345-015-0030-4.","journal-title":"Int J Bipolar Disord"},{"key":"ref12","first-page":"275","volume-title":"Anxiety and Depression Association of America patient guide to mood and anxiety disorders","author":"Frye MA","year":"2024","unstructured":"Frye MA, Singh B. Other anticonvulsants: Pregabalin, gabapentin, and topiramate. In: Nemeroff CB, Craighead WE, editors. Anxiety and Depression Association of America patient guide to mood and anxiety disorders. Amer Psychiatric Pub Inc; 2024. pp. 275\u201380."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/eip.12900","article-title":"Clinical features and patterns of psychopharmacological prescription in bipolar patients with vs without anxiety disorders at onset","volume":"14","author":"Galimberti C","year":"2020","unstructured":"Galimberti C, Caricasole V, Bosi MF, Vigano CA, Ketter TA, Dell'Osso B. Clinical features and patterns of psychopharmacological prescription in bipolar patients with vs without anxiety disorders at onset. Early Interv Psychiatry. 2020;14:714\u201322. https:\/\/doi.org\/10.1111\/eip.12900.","journal-title":"Early Interv Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jad.2022.05.037","article-title":"Quantification of diet quality utilizing the rapid eating assessment for participants-shortened version in bipolar disorder: Implications for prospective depression and cardiometabolic studies","volume":"310","author":"Gardea-Resendez M","year":"2022","unstructured":"Gardea-Resendez M, Winham SJ, Romo-Nava F, Cuellar-Barboza A, Clark MM, Andreazza AC, Cabello-Arreola A, Veldic M, Bond DJ, Singh B, Prieto ML, Nunez NA, Betcher H, Moore KM, Blom T, Colby C, Pendegraft RS, Kelpin SS, Ozerdem A, Miola A, De Filippis E, Biernacka JM, McElroy SL, Frye MA. Quantification of diet quality utilizing the rapid eating assessment for participants-shortened version in bipolar disorder: Implications for prospective depression and cardiometabolic studies. J Affect Disord. 2022;310:150\u20135. https:\/\/doi.org\/10.1016\/j.jad.2022.05.037.","journal-title":"J Affect Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/da.20053","article-title":"Anxiety disorder comobidity in Bipolar I Disorder: relationship to depression severity and treatment outcome","volume":"21","author":"Gaudiano BA","year":"2005","unstructured":"Gaudiano BA, Miller IW. Anxiety disorder comobidity in Bipolar I Disorder: relationship to depression severity and treatment outcome. Depress Anxiety. 2005;21:71\u20137. https:\/\/doi.org\/10.1002\/da.20053.","journal-title":"Depress Anxiety"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4088\/JCP.v63n1013","article-title":"Is response to prophylactic lithium a familial trait?","volume":"63","author":"Grof P","year":"2002","unstructured":"Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O'Donovan C, Alda M. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63:942\u20137.","journal-title":"J Clin Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4088\/jcp.v67n0304","article-title":"Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study","volume":"67","author":"Hirschfeld RM","year":"2006","unstructured":"Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, Group BS. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67:355\u201362. https:\/\/doi.org\/10.4088\/jcp.v67n0304.","journal-title":"J Clin Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/cpt.1982","article-title":"Mood-Stabilizing Antiepileptic Treatment Response in Bipolar Disorder: A Genome-Wide Association Study","volume":"108","author":"Ho AM","year":"2020","unstructured":"Ho AM, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, Nassan M, Colby CL, Larrabee BR, Weinshilboum RM, Frye MA, Biernacka JM. Mood-Stabilizing Antiepileptic Treatment Response in Bipolar Disorder: A Genome-Wide Association Study. Clin Pharmacol Ther. 2020;108:1233\u201342. https:\/\/doi.org\/10.1002\/cpt.1982.","journal-title":"Clin Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jad.2022.04.025","article-title":"The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression","volume":"308","author":"Jones G","year":"2022","unstructured":"Jones G, Rong C, Vecera CM, Gurguis CI, Chudal R, Khairova R, Leung E, Ruiz AC, Shahani L, Zanetti MV, de Sousa RT, Busatto G, Soares J, Gattaz WF, Machado-Vieira R. The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression. J Affect Disord. 2022;308:71\u20135. https:\/\/doi.org\/10.1016\/j.jad.2022.04.025.","journal-title":"J Affect Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/brainsci13010133","article-title":"Long-Term Lithium Therapy and Thyroid Disorders in Bipolar Disorder: A Historical Cohort Study","author":"Joseph B","year":"2023","unstructured":"Joseph B, Nunez NA, Pazdernik V, Kumar R, Pahwa M, Ercis M, Ozerdem A, Cuellar-Barboza AB, Romo-Nava F, McElroy SL, Coombes BJ, Biernacka JM, Stan MN, Frye MA, Singh B. Long-Term Lithium Therapy and Thyroid Disorders in Bipolar Disorder: A Historical Cohort Study. Brain Sci. 2023;13. https:\/\/doi.org\/10.3390\/brainsci13010133.","journal-title":"Brain Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2165\/11310850-000000000-00000","article-title":"Epidemiology and management of anxiety in patients with bipolar disorder","volume":"23","author":"Kauer-Sant'Anna M","year":"2009","unstructured":"Kauer-Sant'Anna M, Kapczinski F, Vieta E. Epidemiology and management of anxiety in patients with bipolar disorder. CNS Drugs. 2009;23:953\u201364. https:\/\/doi.org\/10.2165\/11310850-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"ref22","first-page":"8","article-title":"Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders","volume":"67","author":"Keck PE","year":"2006","unstructured":"Keck PE Jr., Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry. 2006;67(Suppl 1):8\u201315.","journal-title":"J Clin Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jad.2018.12.039","article-title":"Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale","volume":"246","author":"Kinrys G","year":"2019","unstructured":"Kinrys G, Bowden CL, Nierenberg AA, Hearing CM, Gold AK, Rabideau DJ, Sylvia LG, Gao K, Kamali M, Bobo WV, Tohen M, Deckersbach T, McElroy SL, Ketter TA, Shelton RC, Friedman ES, Calabrese JR, McInnis MG, Kocsis J, Thase ME, Singh V, Reilly-Harrington NA. Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. J Affect Disord. 2019;246:126\u201331. https:\/\/doi.org\/10.1016\/j.jad.2018.12.039.","journal-title":"J Affect Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41398-020-00981-5","article-title":"Polygenic risk for anxiety influences anxiety comorbidity and suicidal behavior in bipolar disorder","volume":"10","author":"Lopes FL","year":"2020","unstructured":"Lopes FL, Zhu K, Purves KL, Song C, Ahn K, Hou L, Akula N, Kassem L, Bergen SE, Landen M, Veras AB, Nardi AE, Study BG, McMahon C, F.J. Polygenic risk for anxiety influences anxiety comorbidity and suicidal behavior in bipolar disorder. Transl Psychiatry. 2020;10:298. https:\/\/doi.org\/10.1038\/s41398-020-00981-5.","journal-title":"Transl Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e70071","DOI":"10.1002\/pcn5.70071","article-title":"Family study of bipolar disorder with comorbid anxiety disorder points to THSD7A with possible role of parent-of-origin effect","volume":"4","author":"Maki H","year":"2025","unstructured":"Maki H, Sakai N, Kataoka M, Fujii K, Kageyama Y, Hayama T, Matsuo K, Nishioka M, Kato T. Family study of bipolar disorder with comorbid anxiety disorder points to THSD7A with possible role of parent-of-origin effect. PCN Rep. 2025;4:e70071. https:\/\/doi.org\/10.1002\/pcn5.70071.","journal-title":"PCN Rep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1176\/appi.ajp.158.3.420","article-title":"Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder","volume":"158","author":"McElroy SL","year":"2001","unstructured":"McElroy SL, Altshuler LL, Suppes T, Keck PE Jr., Frye MA, Denicoff KD, Nolen WA, Kupka RW, Leverich GS, Rochussen JR, Rush AJ, Post RM. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001;158:420\u20136. https:\/\/doi.org\/10.1176\/appi.ajp.158.3.420.","journal-title":"Am J Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1399-5618.2006.00355.x","article-title":"Anxiety disorders and bipolar disorder: a review","volume":"8","author":"McIntyre RS","year":"2006","unstructured":"McIntyre RS, Soczynska JK, Bottas A, Bordbar K, Konarski JZ, Kennedy SH. Anxiety disorders and bipolar disorder: a review. Bipolar Disord. 2006;8:665\u201376. https:\/\/doi.org\/10.1111\/j.1399-5618.2006.00355.x.","journal-title":"Bipolar Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas KR","year":"2007","unstructured":"Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543\u201352. https:\/\/doi.org\/10.1001\/archpsyc.64.5.543.","journal-title":"Arch Gen Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/acps.12005","article-title":"Bipolar disorder in a national survey using the World Mental Health Version of the Composite International Diagnostic Interview: the impact of differing diagnostic algorithms","volume":"127","author":"Mitchell PB","year":"2013","unstructured":"Mitchell PB, Johnston AK, Frankland A, Slade T, Green MJ, Roberts G, Wright A, Corry J, Hadzi-Pavlovic D. Bipolar disorder in a national survey using the World Mental Health Version of the Composite International Diagnostic Interview: the impact of differing diagnostic algorithms. Acta Psychiatr Scand. 2013;127:381\u201393. https:\/\/doi.org\/10.1111\/acps.12005.","journal-title":"Acta Psychiatr Scand"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/bdi.13052","article-title":"Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study","volume":"23","author":"Pahwa M","year":"2021","unstructured":"Pahwa M, Joseph B, Nunez NA, Jenkins GD, Colby CL, Kashani KB, Marin V, Moore KM, Betcher HK, Ozerdem A, Cuellar-Barboza AB, McElroy SL, Biernacka JM, Frye MA, Singh B. Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study. Bipolar Disord. 2021a;23:715\u201323. https:\/\/doi.org\/10.1111\/bdi.13052.","journal-title":"Bipolar Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13052","article-title":"2021b. Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study","author":"Pahwa M","unstructured":"Pahwa M, Joseph B, Nunez NA, Jenkins GD, Colby CL, Kashani KB, Marin V, Moore KM, Betcher HK, Ozerdem A, Cuellar-Barboza AB, McElroy SL, Biernacka JM, Frye MA, Singh B. 2021b. Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study. Bipolar Disord. https:\/\/doi.org\/10.1111\/bdi.13052","journal-title":"Bipolar Disord"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.64719\/pb.4433","article-title":"Short Term Second-Generation Antidepressant Monotherapy in Acute Depressive Episodes of Bipolar II Disorder: A Systematic Review and Meta-Analysis","volume":"52","author":"Park JH","year":"2022","unstructured":"Park JH, Nunez NA, Gardea-Resendez M, Gerberi DJ, Breitinger S, Veldic M, Frye MA, Singh B. Short Term Second-Generation Antidepressant Monotherapy in Acute Depressive Episodes of Bipolar II Disorder: A Systematic Review and Meta-Analysis. Psychopharmacol Bull. 2022;52:45\u201372.","journal-title":"Psychopharmacol Bull"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S2215-0366(15)00112-1","article-title":"Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis","volume":"2","author":"Pavlova B","year":"2015","unstructured":"Pavlova B, Perlis RH, Alda M, Uher R. Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry. 2015;2:710\u20137. https:\/\/doi.org\/10.1016\/S2215-0366(15)00112-1.","journal-title":"Lancet Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam","volume":"62","author":"Rickels K","year":"2005","unstructured":"Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022\u201330. https:\/\/doi.org\/10.1001\/archpsyc.62.9.1022.","journal-title":"Arch Gen Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jad.2021.08.026","article-title":"Revisiting the bipolar disorder with migraine phenotype: Clinical features and comorbidity","volume":"295","author":"Romo-Nava F","year":"2021","unstructured":"Romo-Nava F, Blom T, Cuellar-Barboza AB, Awosika OO, Martens BE, Mori NN, Colby CL, Prieto ML, Veldic M, Singh B, Gardea-Resendez M, Nunez NA, Ozerdem A, Biernacka JM, Frye MA, McElroy SL. Revisiting the bipolar disorder with migraine phenotype: Clinical features and comorbidity. J Affect Disord. 2021;295:156\u201362. https:\/\/doi.org\/10.1016\/j.jad.2021.08.026.","journal-title":"J Affect Disord"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","article-title":"A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients","volume":"56","author":"Salvi F","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, Spazzafumo L, Mancinelli L, Espinosa E, Rappelli A, Dessi-Fulgheri P. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008;56:1926\u201331. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01935.x.","journal-title":"J Am Geriatr Soc"},{"key":"ref37","author":"Schaffer A","year":"2012","unstructured":"Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN, Canadian Network for, Task MAT. F., 2012. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 24, 6\u201322."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jad.2012.07.016","article-title":"Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient","volume":"145","author":"Sheehan DV","year":"2013","unstructured":"Sheehan DV, Harnett-Sheehan K, Hidalgo RB, Janavs J, McElroy SL, Amado D, Suppes T. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord. 2013;145:83\u201394. https:\/\/doi.org\/10.1016\/j.jad.2012.07.016.","journal-title":"J Affect Disord"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1176\/appi.ajp.161.12.2222","article-title":"Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"161","author":"Simon NM","year":"2004","unstructured":"Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, Sachs GS, Nierenberg AA, Thase ME, Pollack MH. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161:2222\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.161.12.2222.","journal-title":"Am J Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-025-00405-7","article-title":"Antipsychotic use in bipolar disorder: clinical and genomic correlates- a Mayo clinic bipolar disorder biobank study","author":"Singh B","year":"2025","unstructured":"Singh B, Ho AM, Coombes BJ, Romo-Nava F, Bond DJ, Veldic M, Pendegraft RS, Batzler A, Cuellar-Barboza AB, Gardea-Resendez M, Prieto ML, Ozerdem A, McElroy SL, Biernacka JM, Frye MA. Antipsychotic use in bipolar disorder: clinical and genomic correlates- a Mayo clinic bipolar disorder biobank study. Int J Bipolar Disord. 2025a. https:\/\/doi.org\/10.1186\/s40345-025-00405-7.","journal-title":"Int J Bipolar Disord"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(25)01140-7","volume":"406","author":"Singh B","year":"2025","unstructured":"Singh B, Swartz HA, Cuellar-Barboza AB, Schaffer A, Kato T, Dols A, Sperry SH, Vassilev AB, Burdick KE, Frye MA. Bipolar disorder Lancet. 2025b;406:963\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(25)01140-7.","journal-title":"Bipolar disorder Lancet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13366","author":"Singh B","year":"2024","unstructured":"Singh B, Yocum AK, Strawbridge R, Burdick KE, Millett CE, Peters AT, Sperry SH, Fico G, Vieta E, Verdolini N, Godin O, Leboyer M, Etain B, Tso IF, Coombes BJ, McInnis MG, Nierenberg AA, Young AH, Ashton MM, Berk M, Williams LJ, Keramatian K, Yatham LN, Overs BJ, Fullerton JM, Roberts G, Mitchell PB, Andreassen OA, Andreazza AC, Zandi PP, Pham D, Biernacka JM, Frye MA, Collaborators F-B. T.G.B.C.C., 2024. Patterns of pharmacotherapy for bipolar disorder: A GBC survey. Bipolar Disord. 26, 22\u201332. https:\/\/doi.org\/10.1111\/bdi.13366"},{"key":"ref43","first-page":"19","article-title":"Anxiety and Substance Use Disorders: A Review","volume":"25","author":"Smith JP","year":"2008","unstructured":"Smith JP, Book SW. Anxiety and Substance Use Disorders: A Review. Psychiatr Times. 2008;25:19\u201323.","journal-title":"Psychiatr Times"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/da.22248","article-title":"Co-occurrence of anxiety and bipolar disorders: clinical and therapeutic overview","volume":"31","author":"Vazquez GH","year":"2014","unstructured":"Vazquez GH, Baldessarini RJ, Tondo L. Co-occurrence of anxiety and bipolar disorders: clinical and therapeutic overview. Depress Anxiety. 2014;31:196\u2013206. https:\/\/doi.org\/10.1002\/da.22248.","journal-title":"Depress Anxiety"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s44220-024-00272-8","article-title":"Characterizing the phenotypic and genetic structure of psychopathology in UK Biobank","volume":"2","author":"Williams CM","year":"2024","unstructured":"Williams CM, Peyre H, Wolfram T, Lee YH, Seidlitz J, Ge T, Smoller JW, Mallard TT, Ramus F. Characterizing the phenotypic and genetic structure of psychopathology in UK Biobank. Nat Ment Health. 2024;2:960\u201374. https:\/\/doi.org\/10.1038\/s44220-024-00272-8.","journal-title":"Nat Ment Health"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fpsyt.2018.00229","article-title":"Prevalence and Associated Features of Anxiety Disorder Comorbidity in Bipolar Disorder: A Meta-Analysis and Meta-Regression Study","volume":"9","author":"Yapici Eser H","year":"2018","unstructured":"Yapici Eser H, Kacar AS, Kilciksiz CM, Yalcinay-Inan M, Ongur D. Prevalence and Associated Features of Anxiety Disorder Comorbidity in Bipolar Disorder: A Meta-Analysis and Meta-Regression Study. Front Psychiatry. 2018;9:229. https:\/\/doi.org\/10.3389\/fpsyt.2018.00229.","journal-title":"Front Psychiatry"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham LN","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609.","journal-title":"Bipolar Disord"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11920-025-01606-8","article-title":"Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder","volume":"27","author":"Yocum AK","year":"2025","unstructured":"Yocum AK, Singh B. Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder. Curr psychiatry Rep. 2025;27:239\u201347. https:\/\/doi.org\/10.1007\/s11920-025-01606-8.","journal-title":"Curr psychiatry Rep"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0165-0327(93)90118-4","article-title":"Anxious and non-anxious bipolar disorder","volume":"29","author":"Young LT","year":"1993","unstructured":"Young LT, Cooke RG, Robb JC, Levitt AJ, Joffe RT. Anxious and non-anxious bipolar disorder. J Affect Disord. 1993;29:49\u201352. https:\/\/doi.org\/10.1016\/0165-0327(93)90118-4.","journal-title":"J Affect Disord"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8503080\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8503080\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:04:35Z","timestamp":1772467475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8503080\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":49,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8503080\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s40345-026-00415-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,1,12]]},"subtype":"preprint"}}